A new myeloid cell engager enters the clinic
After Dren secured buy-in from Novartis, LTZ becomes a clinical player.
Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
World Lung 2025 preview – best of the rest
Posters and mini-orals include another VEGF bispecific.
World Lung 2025 preview – late-breakers in focus
Summit and Nuvalent have scored prized plenary spots.
Otsuka zips into adjuvant use
As a second-line zipalertinib filing approaches, Otsuka goes earlier and broader.
A mystery Moderna asset hits the clinic
mRNA-2808 could be a multispecific mRNA-encoded T-cell engager therapy.
